Clinical Trial Update: IPO-NEC Trial:Study on the Efficacy and Safety Using Sequential IP Therapy and Oct Lar in the Treatment of Advanced GI NEC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating sequential intraperitoneal therapy and octreotide long-acting release for advanced gastrointestinal neuroendocrine carcinoma h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Neuroendocrine Carcinoma

Drugs mentioned

• Sandostatin LAR (octreotide)

Snippet

Sponsor: Peking University | Conditions: Progression Free Survival of the Treatment | Phase 2 | Status: COMPLETED